Datasets:
vgainullin
/
xciting_data

Dataset card Data Studio Files
xet
 Community
1
paragraph_index
int64
sec
string
p_has_citation
int64
cites
string
citeids
list
pmid
int64
cited_id
string
sentences
string
all_sent_cites
list
sent_len
int64
sentence_batch_index
int64
sent_has_citation
float64
qc_fail
bool
cited_sentence
string
cites_in_sentence
list
cln_sentence
string
is_cap
bool
is_alpha
bool
ends_wp
bool
cit_qc
bool
lgtm
bool
__index_level_0__
int64
4
DISCUSSION
1
9
[ "B9", "B10", "B14" ]
20,635,453
pmid-15096568|pmid-9854054|pmid-16886150
Our results of the two multiplex PCR showed an equivalent or higher positive rate than in other studies.9,10,14 Two kinds of multiplex PCR reagents showed different positivity according to the virus type.
[ "9", "10", "14" ]
204
39,416
0
false
Our results of the two multiplex PCR showed an equivalent or higher positive rate than in other studies.9,10,14 Two kinds of multiplex PCR reagents showed different positivity according to the virus type.
[]
Our results of the two multiplex PCR showed an equivalent or higher positive rate than in other studies.9,10,14 Two kinds of multiplex PCR reagents showed different positivity according to the virus type.
true
true
true
true
true
6,798
4
DISCUSSION
1
9
[ "B9", "B10", "B14" ]
20,635,453
pmid-15096568|pmid-9854054|pmid-16886150
The positive rate of the Seeplex™ RV detection kit was higher than the Labopass™ RV kit for IFV and RhV.
[ "9", "10", "14" ]
104
39,417
0
false
The positive rate of the Seeplex™ RV detection kit was higher than the Labopass™ RV kit for IFV and RhV.
[]
The positive rate of the Seeplex™ RV detection kit was higher than the Labopass™ RV kit for IFV and RhV.
true
true
true
true
true
6,798
4
DISCUSSION
1
9
[ "B9", "B10", "B14" ]
20,635,453
pmid-15096568|pmid-9854054|pmid-16886150
However, the Labopass™ RV kit detected more HMPV than the Seeplex™ RV kit.
[ "9", "10", "14" ]
74
39,418
0
false
However, the Labopass™ RV kit detected more HMPV than the Seeplex™ RV kit.
[]
However, the Labopass™ RV kit detected more HMPV than the Seeplex™ RV kit.
true
true
true
true
true
6,798
5
DISCUSSION
1
17
[ "B17", "B17", "B20" ]
20,635,453
pmid-14767825|pmid-14767825|pmid-18316781
Discrepant results between these two types of multiplex PCR and R-Mix culture comprised 51.5% (53/103) of the total.
[ "17", "17", "20" ]
116
39,419
0
false
Discrepant results between these two types of multiplex PCR and R-Mix culture comprised 51.5% (53/103) of the total.
[]
Discrepant results between these two types of multiplex PCR and R-Mix culture comprised 51.5% of the total.
true
true
true
true
true
6,799
5
DISCUSSION
1
17
[ "B17", "B17", "B20" ]
20,635,453
pmid-14767825|pmid-14767825|pmid-18316781
Weinberg, et al.17 reported that the PCR method could detect viruses two times more, compared with virus culture.
[ "17", "17", "20" ]
113
39,420
0
false
Weinberg, et al.17 reported that the PCR method could detect viruses two times more, compared with virus culture.
[]
Weinberg, et al.17 reported that the PCR method could detect viruses two times more, compared with virus culture.
true
true
true
true
true
6,799
5
DISCUSSION
1
17
[ "B17", "B17", "B20" ]
20,635,453
pmid-14767825|pmid-14767825|pmid-18316781
Our study showed that the concordance rate of Seeplex PCR to the virus culture was 83% (90/103), and that of Labopass PCR, 80.6% (83/103).
[ "17", "17", "20" ]
138
39,421
0
false
Our study showed that the concordance rate of Seeplex PCR to the virus culture was 83% (90/103), and that of Labopass PCR, 80.6% (83/103).
[]
Our study showed that the concordance rate of Seeplex PCR to the virus culture was 83%, and that of Labopass PCR, 80.6%.
true
true
true
true
true
6,799
5
DISCUSSION
1
17
[ "B17", "B17", "B20" ]
20,635,453
pmid-14767825|pmid-14767825|pmid-18316781
These results were similar to previous reports, of 83.2% (556/668)17 and 80% (40/50).20
[ "17", "17", "20" ]
87
39,422
0
false
These results were similar to previous reports, of 83.2% (556/668)17 and 80% (40/50).20
[]
These results were similar to previous reports, of 83.2% (556/668)17 and 80% (40/50).20
true
true
false
true
false
6,799
6
DISCUSSION
1
9
[ "B9", "B21" ]
20,635,453
pmid-15096568|pmid-17223623
The discrepancy might be caused from multiplex PCR limitations.
[ "9", "21" ]
63
39,423
0
false
The discrepancy might be caused from multiplex PCR limitations.
[]
The discrepancy might be caused from multiplex PCR limitations.
true
true
true
true
true
6,800
6
DISCUSSION
1
9
[ "B9", "B21" ]
20,635,453
pmid-15096568|pmid-17223623
One of the major limitations of PCR detection is false-negative results as a consequence of PCR inhibitors present in clinical samples that are not removed by the extraction process.9 Another limitation is the principle of PCRs, which could produce false results if a primer region has nucleotide variation and is unable...
[ "9", "21" ]
363
39,424
0
false
One of the major limitations of PCR detection is false-negative results as a consequence of PCR inhibitors present in clinical samples that are not removed by the extraction process.9 Another limitation is the principle of PCRs, which could produce false results if a primer region has nucleotide variation and is unable...
[]
One of the major limitations of PCR detection is false-negative results as a consequence of PCR inhibitors present in clinical samples that are not removed by the extraction process.9 Another limitation is the principle of PCRs, which could produce false results if a primer region has nucleotide variation and is unable...
true
true
true
true
true
6,800
6
DISCUSSION
1
9
[ "B9", "B21" ]
20,635,453
pmid-15096568|pmid-17223623
This is the reason that direct antigen tests or virus cultures cannot be completely substituted by solitary multiplex PCR tests until now.21
[ "9", "21" ]
140
39,425
0
false
This is the reason that direct antigen tests or virus cultures cannot be completely substituted by solitary multiplex PCR tests until now.21
[]
This is the reason that direct antigen tests or virus cultures cannot be completely substituted by solitary multiplex PCR tests until now.21
true
true
false
true
false
6,800
7
DISCUSSION
1
22
[ "B22" ]
20,635,453
pmid-16007532
We noticed a 6.8% (15/220) coinfection rate (more than 2 virus types identified) by the Seeplex™ RV kit and 5.9% (13/220) by the Labopass™ RV kit.
[ "22" ]
146
39,426
0
false
We noticed a 6.8% coinfection rate (more than 2 virus types identified) by the Seeplex™ RV kit and 5.9% by the Labopass™ RV kit.
[ "15/220", "13/220" ]
We noticed a 6.8% coinfection rate by the Seeplex™ RV kit and 5.9% by the Labopass™ RV kit.
true
true
true
true
true
6,801
7
DISCUSSION
1
22
[ "B22" ]
20,635,453
pmid-16007532
Previous studies have suggested that double-virus infections are associated with greater severity of respiratory tract infection.22 In our study, we could not find out any remarkable parameters or difference of clinical severity in cases of coinfection.
[ "22" ]
253
39,427
0
false
Previous studies have suggested that double-virus infections are associated with greater severity of respiratory tract infection.22 In our study, we could not find out any remarkable parameters or difference of clinical severity in cases of coinfection.
[]
Previous studies have suggested that double-virus infections are associated with greater severity of respiratory tract infection.22 In our study, we could not find out any remarkable parameters or difference of clinical severity in cases of coinfection.
true
true
true
true
true
6,801
8
DISCUSSION
0
null
null
20,635,453
null
Ten cases of culture negative but multiplex PCR positive were further evaluated by direct sequencing in our study.
null
114
39,428
0
false
null
null
Ten cases of culture negative but multiplex PCR positive were further evaluated by direct sequencing in our study.
true
true
true
true
true
6,802
8
DISCUSSION
0
null
null
20,635,453
null
Sequencing results confirmed almost all the original results of multiplex PCR.
null
78
39,429
0
false
null
null
Sequencing results confirmed almost all the original results of multiplex PCR.
true
true
true
true
true
6,802
9
DISCUSSION
0
null
null
20,635,453
null
In conclusion, identification of respiratory viruses by multiplex PCR can be more rapid, an easier method, and show more positive results than the viral culture method.
null
168
39,430
0
false
null
null
In conclusion, identification of respiratory viruses by multiplex PCR can be more rapid, an easier method, and show more positive results than the viral culture method.
true
true
true
true
true
6,803
9
DISCUSSION
0
null
null
20,635,453
null
Hence, multiplex PCR can be the first choice for detection of respiratory viruses in a clinical laboratory.
null
107
39,431
0
false
null
null
Hence, multiplex PCR can be the first choice for detection of respiratory viruses in a clinical laboratory.
true
true
true
true
true
6,803
9
DISCUSSION
0
null
null
20,635,453
null
Other complementary efforts such as viral cultures and sequencing methods could be selectively proceeded in selected cases according to each laboratory's environment.
null
166
39,432
0
false
null
null
Other complementary efforts such as viral cultures and sequencing methods could be selectively proceeded in selected cases according to each laboratory's environment.
true
true
true
true
true
6,803
0
INTRODUCTION
1
1
[ "CR1", "CR2", "CR1", "CR3", "CR3", "CR4" ]
20,229,139
doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2
Pain is a common debilitating condition.
[ "1", "2", "1", "3", "3", "4" ]
40
39,433
0
false
Pain is a common debilitating condition.
[]
Pain is a common debilitating condition.
true
true
true
true
true
6,804
0
INTRODUCTION
1
1
[ "CR1", "CR2", "CR1", "CR3", "CR3", "CR4" ]
20,229,139
doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2
Approximately 20% of patients and 25% to 50% of community-dwelling elders experience chronic pain.1,2Although many studies have identified under-treatment of pain,1–3 few have examined why providers vary in responding to patient-reported pain.3,4 Such information would help inform more successful approaches to pain man...
[ "1", "2", "1", "3", "3", "4" ]
328
39,434
0
false
Approximately 20% of patients and 25% to 50% of community-dwelling elders experience chronic pain.1,2Although many studies have identified under-treatment of pain,1–3 few have examined why providers vary in responding to patient-reported pain.3,4 Such information would help inform more successful approaches to pain man...
[]
Approximately 20% of patients and 25% to 50% of community-dwelling elders experience chronic pain.1,2Although many studies have identified under-treatment of pain,1–3 few have examined why providers vary in responding to patient-reported pain.3,4 Such information would help inform more successful approaches to pain man...
true
true
true
true
true
6,804
1
INTRODUCTION
1
3
[ "CR3", "CR4", "CR3", "CR5", "CR9", "CR3", "CR6", "CR7" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
In 2003, the Department of Veterans Affairs (VA) implemented the “5th vital sign”—a rating also known as the numeric rating scale (NRS)3,4 to assure routine pain assessment and improve management.3,5–9
[ "3", "4", "3", "5", "9", "3", "6", "7" ]
201
39,435
0
false
In 2003, the Department of Veterans Affairs (VA) implemented the “5th vital sign”—a rating also known as the numeric rating scale (NRS)3,4 to assure routine pain assessment and improve management.3,5–9
[]
In 2003, the Department of Veterans Affairs (VA) implemented the “5th vital sign”—a rating also known as the numeric rating scale (NRS)3,4 to assure routine pain assessment and improve management.3,5–9
true
true
false
true
false
6,805
1
INTRODUCTION
1
3
[ "CR3", "CR4", "CR3", "CR5", "CR9", "CR3", "CR6", "CR7" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
The NRS asks veteran patients to rate current pain from zero or “no pain” to ten or “worst possible pain”.3,6,7
[ "3", "4", "3", "5", "9", "3", "6", "7" ]
111
39,436
0
false
The NRS asks veteran patients to rate current pain from zero or “no pain” to ten or “worst possible pain”.3,6,7
[]
The NRS asks veteran patients to rate current pain from zero or “no pain” to ten or “worst possible pain”.3,6,7
true
true
false
true
false
6,805
2
INTRODUCTION
1
5
[ "CR5", "CR3" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
Moderate to severe pain, measured by a score on the NRS between four and ten, should typically trigger a comprehensive pain assessment and prompt intervention.5 However, one study at a single VA medical center, found that routine pain screening did not change provider medication management.3 That study occurred soon af...
[ "5", "3" ]
483
39,437
0
false
Moderate to severe pain, measured by a score on the NRS between four and ten, should typically trigger a comprehensive pain assessment and prompt intervention.5 However, one study at a single VA medical center, found that routine pain screening did not change provider medication management.3 That study occurred soon af...
[]
Moderate to severe pain, measured by a score on the NRS between four and ten, should typically trigger a comprehensive pain assessment and prompt intervention.5 However, one study at a single VA medical center, found that routine pain screening did not change provider medication management.3 That study occurred soon af...
true
true
true
true
true
6,806
2
INTRODUCTION
1
5
[ "CR5", "CR3" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
This study builds on earlier work in developing an assessment across multiple sites with established NRS procedures and examines multiple processes of care, from assessment of pain to treatment.
[ "5", "3" ]
194
39,438
0
false
This study builds on earlier work in developing an assessment across multiple sites with established NRS procedures and examines multiple processes of care, from assessment of pain to treatment.
[]
This study builds on earlier work in developing an assessment across multiple sites with established NRS procedures and examines multiple processes of care, from assessment of pain to treatment.
true
true
true
true
true
6,806
3
INTRODUCTION
0
null
null
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
We examined indicators of four key processes of pain evaluation and management in a regional cohort of facilities where routine pain screening was implemented during the last 10 years.
null
184
39,439
0
false
null
null
We examined indicators of four key processes of pain evaluation and management in a regional cohort of facilities where routine pain screening was implemented during the last 10 years.
true
true
true
true
true
6,807
3
INTRODUCTION
0
null
null
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
We estimated adherence to these indicators and examined patient and provider factors associated with these processes of care.
null
125
39,440
0
false
null
null
We estimated adherence to these indicators and examined patient and provider factors associated with these processes of care.
true
true
true
true
true
6,807
0
DISCUSSION
0
null
null
20,229,139
doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2
We found that among patients who reported moderate to severe pain at an appointment, providers often noted the presence of pain but did not clinically evaluate it further or modify pharmacologic treatment.
null
205
39,441
0
false
null
null
We found that among patients who reported moderate to severe pain at an appointment, providers often noted the presence of pain but did not clinically evaluate it further or modify pharmacologic treatment.
true
true
true
true
true
6,808
0
DISCUSSION
0
null
null
20,229,139
doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1016/S0304-3959(00)00483-8|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2
Provider attitudes were weak predictors of adherence to quality indicators, although some provider attitudes toward the NRS were correlated with QI adherence.
null
158
39,442
0
false
null
null
Provider attitudes were weak predictors of adherence to quality indicators, although some provider attitudes toward the NRS were correlated with QI adherence.
true
true
true
true
true
6,808
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
Similar to prior studies, 3,6,25 our results question whether the 5th vital sign has substantively improved pain assessment and management.
[ "3", "6", "25", "3", "14", "18", "3" ]
139
39,443
0
false
Similar to prior studies, 3,6,25 our results question whether the 5th vital sign has substantively improved pain assessment and management.
[]
Similar to prior studies, 3,6,25 our results question whether the 5th vital sign has substantively improved pain assessment and management.
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
More notably, Mularski et al.3 reported that NRS implementation did not change visit-associated pain documentation or treatment intensification.
[ "3", "6", "25", "3", "14", "18", "3" ]
144
39,444
0
false
More notably, Mularski et al.3 reported that NRS implementation did not change visit-associated pain documentation or treatment intensification.
[]
More notably, Mularski et al.3 reported that NRS implementation did not change visit-associated pain documentation or treatment intensification.
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
Our results extend previous work in three ways.
[ "3", "6", "25", "3", "14", "18", "3" ]
47
39,445
0
false
Our results extend previous work in three ways.
[]
Our results extend previous work in three ways.
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
First, our indicators were closely adapted from ACOVE14–18 and were subjected to a rigorous development process.
[ "3", "6", "25", "3", "14", "18", "3" ]
112
39,446
0
false
First, our indicators were closely adapted from ACOVE14–18 and were subjected to a rigorous development process.
[]
First, our indicators were closely adapted from ACOVE14–18 and were subjected to a rigorous development process.
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
As such, the quality indicators allowed us to more broadly measure processes of care (i.e., notation, character and severity of pain).
[ "3", "6", "25", "3", "14", "18", "3" ]
134
39,447
0
false
As such, the quality indicators allowed us to more broadly measure processes of care (i.e., notation, character and severity of pain).
[]
As such, the quality indicators allowed us to more broadly measure processes of care (i.e., notation, character and severity of pain).
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
Second, Mularski et al.3 conducted their study between 1999 and 2001, soon after the institution of the NRS when providers were perhaps not familiar with it.
[ "3", "6", "25", "3", "14", "18", "3" ]
157
39,448
0
false
Second, Mularski et al.3 conducted their study between 1999 and 2001, soon after the institution of the NRS when providers were perhaps not familiar with it.
[]
Second, Mularski et al.3 conducted their study between 1999 and 2001, soon after the institution of the NRS when providers were perhaps not familiar with it.
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
Our results, a decade later, suggest the screening tool still has had limited impact on pain management.
[ "3", "6", "25", "3", "14", "18", "3" ]
104
39,449
0
false
Our results, a decade later, suggest the screening tool still has had limited impact on pain management.
[]
Our results, a decade later, suggest the screening tool still has had limited impact on pain management.
true
true
true
true
true
6,809
1
DISCUSSION
1
3
[ "CR3", "CR6", "CR25", "CR3", "CR14", "CR18", "CR3" ]
20,229,139
doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1007/s11606-007-0321-2|doi-10.1111/j.1525-1497.2006.00415.x|NA|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.3122/jabfm.2009.03.080162|doi-10.1016/j.cardfail.2008.09.002|doi-10.1111/j.1525-1497.2006.004...
Third, our work extends Mularski’s findings from a single VA site to multiple sites.
[ "3", "6", "25", "3", "14", "18", "3" ]
84
39,450
0
false
Third, our work extends Mularski’s findings from a single VA site to multiple sites.
[]
Third, our work extends Mularski’s findings from a single VA site to multiple sites.
true
true
true
true
true
6,809
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
Why the 5th vital sign has not produced more substantive improvements is unclear.
[ "22", "26" ]
81
39,451
0
false
Why the 5th vital sign has not produced more substantive improvements is unclear.
[]
Why the 5th vital sign has not produced more substantive improvements is unclear.
true
true
true
true
true
6,810
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
One possibility is the NRS does not accurately represent pain levels or that providers do not perceive it as accurate, and hence do not act based on the rating scale.
[ "22", "26" ]
166
39,452
0
false
One possibility is the NRS does not accurately represent pain levels or that providers do not perceive it as accurate, and hence do not act based on the rating scale.
[]
One possibility is the NRS does not accurately represent pain levels or that providers do not perceive it as accurate, and hence do not act based on the rating scale.
true
true
true
true
true
6,810
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
Indeed, 12% of providers disagreed or strongly disagreed that “patients are able to rate their own pain intensity on the 0–10 scale” (Table 1), suggesting concern with the tool.
[ "22", "26" ]
177
39,453
0
false
Indeed, 12% of providers disagreed or strongly disagreed that “patients are able to rate their own pain intensity on the 0–10 scale” (Table 1), suggesting concern with the tool.
[]
Indeed, 12% of providers disagreed or strongly disagreed that “patients are able to rate their own pain intensity on the 0–10 scale” (Table 1), suggesting concern with the tool.
true
true
true
true
true
6,810
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
Another possibility is that providers do not approach pain evaluation uniformly.
[ "22", "26" ]
80
39,454
0
false
Another possibility is that providers do not approach pain evaluation uniformly.
[]
Another possibility is that providers do not approach pain evaluation uniformly.
true
true
true
true
true
6,810
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
Chronic pain patients are vexing for many providers22–26 and the subjective nature of pain likely adds to variance in addressing it.
[ "22", "26" ]
132
39,455
0
false
Chronic pain patients are vexing for many providers22–26 and the subjective nature of pain likely adds to variance in addressing it.
[]
Chronic pain patients are vexing for many providers22–26 and the subjective nature of pain likely adds to variance in addressing it.
true
true
true
true
true
6,810
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
While rating pain numerically may create a standard measurement, it may not yield a standardized approach to its subsequent evaluation and management.
[ "22", "26" ]
150
39,456
0
false
While rating pain numerically may create a standard measurement, it may not yield a standardized approach to its subsequent evaluation and management.
[]
While rating pain numerically may create a standard measurement, it may not yield a standardized approach to its subsequent evaluation and management.
true
true
true
true
true
6,810
2
DISCUSSION
1
22
[ "CR22", "CR26" ]
20,229,139
NA|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1526-4637.2007.00330.x|doi-10.1007/s11606-009-0956-2
Further research is needed on variations in pain management but, in the meantime, providers and patients might benefit from clinical decision support tools (e.g., clinical reminders) within CPRS.
[ "22", "26" ]
195
39,457
0
false
Further research is needed on variations in pain management but, in the meantime, providers and patients might benefit from clinical decision support tools (e.g., clinical reminders) within CPRS.
[]
Further research is needed on variations in pain management but, in the meantime, providers and patients might benefit from clinical decision support tools (e.g., clinical reminders) within CPRS.
true
true
true
true
true
6,810
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Measuring pain management poses unique methodological challenges.
[ "2", "3", "17", "20", "23", "24" ]
65
39,458
0
false
Measuring pain management poses unique methodological challenges.
[]
Measuring pain management poses unique methodological challenges.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Chart review may not be optimal (for example, pharmacy records may not represent all provider actions), though it remains the current gold standard.
[ "2", "3", "17", "20", "23", "24" ]
148
39,459
0
false
Chart review may not be optimal (for example, pharmacy records may not represent all provider actions), though it remains the current gold standard.
[]
Chart review may not be optimal (for example, pharmacy records may not represent all provider actions), though it remains the current gold standard.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
However, our study looked for new or adjusted prescriptions within 90 days of a visit to evaluate for initiation or intensification.
[ "2", "3", "17", "20", "23", "24" ]
132
39,460
0
false
However, our study looked for new or adjusted prescriptions within 90 days of a visit to evaluate for initiation or intensification.
[]
However, our study looked for new or adjusted prescriptions within 90 days of a visit to evaluate for initiation or intensification.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Even so, our results identified a divergence between providers’ self-described actions and pharmacy records.
[ "2", "3", "17", "20", "23", "24" ]
108
39,461
0
false
Even so, our results identified a divergence between providers’ self-described actions and pharmacy records.
[]
Even so, our results identified a divergence between providers’ self-described actions and pharmacy records.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
This could point to inaccurate information reflected in the pharmacy records, although this is unlikely within the VA.
[ "2", "3", "17", "20", "23", "24" ]
118
39,462
0
false
This could point to inaccurate information reflected in the pharmacy records, although this is unlikely within the VA.
[]
This could point to inaccurate information reflected in the pharmacy records, although this is unlikely within the VA.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
However, our pharmacy data did not include non-VA prescriptions and this may have importance since some patients, particularly those who have an $8 per month co-payment for each prescription, purchase medications privately.
[ "2", "3", "17", "20", "23", "24" ]
223
39,463
0
false
However, our pharmacy data did not include non-VA prescriptions and this may have importance since some patients, particularly those who have an $8 per month co-payment for each prescription, purchase medications privately.
[]
However, our pharmacy data did not include non-VA prescriptions and this may have importance since some patients, particularly those who have an $8 per month co-payment for each prescription, purchase medications privately.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Several non-pharmaceutical intensification strategies were reported by patients to be useful (e.g., physical therapy, ice).
[ "2", "3", "17", "20", "23", "24" ]
123
39,464
0
false
Several non-pharmaceutical intensification strategies were reported by patients to be useful (e.g., physical therapy, ice).
[]
Several non-pharmaceutical intensification strategies were reported by patients to be useful (e.g., physical therapy, ice).
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Also, at times, initiation or intensification may not have been the most appropriate clinical action.
[ "2", "3", "17", "20", "23", "24" ]
101
39,465
0
false
Also, at times, initiation or intensification may not have been the most appropriate clinical action.
[]
Also, at times, initiation or intensification may not have been the most appropriate clinical action.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
When intensification did not occur at the visit, providers most commonly reported that patient preference was not to change treatment, “everything had been done”, or the patient was not experiencing pain.
[ "2", "3", "17", "20", "23", "24" ]
204
39,466
0
false
When intensification did not occur at the visit, providers most commonly reported that patient preference was not to change treatment, “everything had been done”, or the patient was not experiencing pain.
[]
When intensification did not occur at the visit, providers most commonly reported that patient preference was not to change treatment, “everything had been done”, or the patient was not experiencing pain.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Furthermore, visit based quality indicators may not be accurate proxies for measuring the quality of pain care at a single visit.
[ "2", "3", "17", "20", "23", "24" ]
129
39,467
0
false
Furthermore, visit based quality indicators may not be accurate proxies for measuring the quality of pain care at a single visit.
[]
Furthermore, visit based quality indicators may not be accurate proxies for measuring the quality of pain care at a single visit.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
Future research could consider longitudinal information to better understand factors influencing pain management.
[ "2", "3", "17", "20", "23", "24" ]
113
39,468
0
false
Future research could consider longitudinal information to better understand factors influencing pain management.
[]
Future research could consider longitudinal information to better understand factors influencing pain management.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
In addition, qualitative interview of providers may help to understand adherence to and predictors of the quality indicators.
[ "2", "3", "17", "20", "23", "24" ]
125
39,469
0
false
In addition, qualitative interview of providers may help to understand adherence to and predictors of the quality indicators.
[]
In addition, qualitative interview of providers may help to understand adherence to and predictors of the quality indicators.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
We examined only VA outpatients, limiting generalizability to other populations and healthcare systems.
[ "2", "3", "17", "20", "23", "24" ]
103
39,470
0
false
We examined only VA outpatients, limiting generalizability to other populations and healthcare systems.
[]
We examined only VA outpatients, limiting generalizability to other populations and healthcare systems.
true
true
true
true
true
6,811
3
DISCUSSION
1
2
[ "CR2", "CR3", "CR17", "CR20", "CR23", "CR24" ]
20,229,139
doi-10.1111/j.1532-5415.2004.52214.x|doi-10.1111/j.1525-1497.2006.00415.x|doi-10.1111/j.1532-5415.2007.01328.x|doi-10.1056/NEJMsa022615|doi-10.1046/j.1526-4637.2002.02022.x|pmid-9092278
However, the VA is a leader in chronic care quality measurement2,3,17,20,23,24 and our study sites implemented routine pain screening a decade ago suggesting our findings represent a ‘best case scenario.’
[ "2", "3", "17", "20", "23", "24" ]
204
39,471
0
false
However, the VA is a leader in chronic care quality measurement2,3,17,20,23,24 and our study sites implemented routine pain screening a decade ago suggesting our findings represent a ‘best case scenario.’
[]
However, the VA is a leader in chronic care quality measurement2,3,17,20,23,24 and our study sites implemented routine pain screening a decade ago suggesting our findings represent a ‘best case scenario.’
true
true
false
true
false
6,811
4
DISCUSSION
1
31
[ "CR31", "CR33" ]
20,229,139
NA|NA
Our study provides greater understanding of how the 5th vital sign and providers’ attitudes toward pain influence the quality of pain care.
[ "31", "33" ]
139
39,472
0
false
Our study provides greater understanding of how the 5th vital sign and providers’ attitudes toward pain influence the quality of pain care.
[]
Our study provides greater understanding of how the 5th vital sign and providers’ attitudes toward pain influence the quality of pain care.
true
true
true
true
true
6,812
4
DISCUSSION
1
31
[ "CR31", "CR33" ]
20,229,139
NA|NA
We found that simply implementing the NRS does not necessarily improve subsequent pain evaluation and management, as measured by four standardized quality indicators.
[ "31", "33" ]
166
39,473
0
false
We found that simply implementing the NRS does not necessarily improve subsequent pain evaluation and management, as measured by four standardized quality indicators.
[]
We found that simply implementing the NRS does not necessarily improve subsequent pain evaluation and management, as measured by four standardized quality indicators.
true
true
true
true
true
6,812
4
DISCUSSION
1
31
[ "CR31", "CR33" ]
20,229,139
NA|NA
Future research should examine what additional provider factors are associated with meeting the quality indicators and consider assessing non-pharmacologic interventions.
[ "31", "33" ]
170
39,474
0
false
Future research should examine what additional provider factors are associated with meeting the quality indicators and consider assessing non-pharmacologic interventions.
[]
Future research should examine what additional provider factors are associated with meeting the quality indicators and consider assessing non-pharmacologic interventions.
true
true
true
true
true
6,812
4
DISCUSSION
1
31
[ "CR31", "CR33" ]
20,229,139
NA|NA
Focused research could include bolstering the 5th vital sign beyond categorizing pain at one point in time; for example, additional screening question(s)31–33 might address whether a patient’s current regimen provides sufficient pain control.
[ "31", "33" ]
242
39,475
0
false
Focused research could include bolstering the 5th vital sign beyond categorizing pain at one point in time; for example, additional screening question(s)31–33 might address whether a patient’s current regimen provides sufficient pain control.
[]
Focused research could include bolstering the 5th vital sign beyond categorizing pain at one point in time; for example, additional screening question(s)31–33 might address whether a patient’s current regimen provides sufficient pain control.
true
true
true
true
true
6,812
4
DISCUSSION
1
31
[ "CR31", "CR33" ]
20,229,139
NA|NA
Whether adding such screening questions would improve pain management is unknown, but it appears that using the NRS scale alone does not guarantee high quality pain management.
[ "31", "33" ]
176
39,476
0
false
Whether adding such screening questions would improve pain management is unknown, but it appears that using the NRS scale alone does not guarantee high quality pain management.
[]
Whether adding such screening questions would improve pain management is unknown, but it appears that using the NRS scale alone does not guarantee high quality pain management.
true
true
true
true
true
6,812
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
This study investigated the differentiation potential of the CX3CR1+ MDPs and the role of CX3CR1 in their development.
[ "24", "25", "9" ]
118
39,477
0
false
This study investigated the differentiation potential of the CX3CR1+ MDPs and the role of CX3CR1 in their development.
[]
This study investigated the differentiation potential of the CX3CR1+ MDPs and the role of CX3CR1 in their development.
true
true
true
true
true
6,813
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
First, our data confirmed that CX3CR1 was associated with the commitment of myeloid progenitors to the monocyte/macrophage/DC lineage.
[ "24", "25", "9" ]
134
39,478
0
false
First, our data confirmed that CX3CR1 was associated with the commitment of myeloid progenitors to the monocyte/macrophage/DC lineage.
[]
First, our data confirmed that CX3CR1 was associated with the commitment of myeloid progenitors to the monocyte/macrophage/DC lineage.
true
true
true
true
true
6,813
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
The recently described CDP (24, 25) also expresses CX3CR1, CD115, and FLT3, and its phenotype was overlapping with the MDP (this study and reference 9).
[ "24", "25", "9" ]
152
39,479
0
false
The recently described CDP also expresses CX3CR1, CD115, and FLT3, and its phenotype was overlapping with the MDP.
[ "24, 25", "this study and reference 9" ]
The recently described CDP also expresses CX3CR1, CD115, and FLT3, and its phenotype was overlapping with the MDP.
true
true
true
true
true
6,813
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
MDP can give rise to both DCs (PDCs and cDCs) and monocytes/macrophages but do not have the potential to give rise to granulocytes.
[ "24", "25", "9" ]
131
39,480
0
false
MDP can give rise to both DCs (PDCs and cDCs) and monocytes/macrophages but do not have the potential to give rise to granulocytes.
[]
MDP can give rise to both DCs (PDCs and cDCs) and monocytes/macrophages but do not have the potential to give rise to granulocytes.
true
true
true
true
true
6,813
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
Thus, they have a more restricted differentiation potential than CMPs, which can give rise to all myeloid cells, and GMPs, which can give rise to granulocytes, macrophages, and DCs (Fig.
[ "24", "25", "9" ]
186
39,481
0
false
Thus, they have a more restricted differentiation potential than CMPs, which can give rise to all myeloid cells, and GMPs, which can give rise to granulocytes, macrophages, and DCs (Fig.
[]
Thus, they have a more restricted differentiation potential than CMPs, which can give rise to all myeloid cells, and GMPs, which can give rise to granulocytes, macrophages, and DCs (Fig.
true
true
true
true
true
6,813
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
CDP has been reported to give rise to cDCs and PDCs but not macrophages and, thus, has a more restricted differentiation potential than MDPs and may be placed downstream (Fig.
[ "24", "25", "9" ]
175
39,482
0
false
CDP has been reported to give rise to cDCs and PDCs but not macrophages and, thus, has a more restricted differentiation potential than MDPs and may be placed downstream (Fig.
[]
CDP has been reported to give rise to cDCs and PDCs but not macrophages and, thus, has a more restricted differentiation potential than MDPs and may be placed downstream (Fig.
true
true
true
true
true
6,813
0
DISCUSSION
1
24
[ "bib24", "bib25", "bib9" ]
19,273,628
NA|NA|NA
Further studies will be needed to investigate the developmental relationship between MDPs and CDPs.
[ "24", "25", "9" ]
99
39,483
0
false
Further studies will be needed to investigate the developmental relationship between MDPs and CDPs.
[]
Further studies will be needed to investigate the developmental relationship between MDPs and CDPs.
true
true
true
true
true
6,813
1
DISCUSSION
0
null
null
19,273,628
null
CX3CR1 is a later marker than CSF-1R in myeloid lineage commitment.
null
67
39,484
0
false
null
null
CX3CR1 is a later marker than CSF-1R in myeloid lineage commitment.
true
true
true
true
true
6,814
1
DISCUSSION
0
null
null
19,273,628
null
In this study, we investigated the role of CX3CR1/CX3CL1 in the development of MDP-derived cells by studying mice lacking CX3CR1 or its ligand CX3CL1/fractalkine during acute and chronic inflammation and in a sensitive competitive adoptive transfer model.
null
255
39,485
0
false
null
null
In this study, we investigated the role of CX3CR1/CX3CL1 in the development of MDP-derived cells by studying mice lacking CX3CR1 or its ligand CX3CL1/fractalkine during acute and chronic inflammation and in a sensitive competitive adoptive transfer model.
true
true
true
true
true
6,814
1
DISCUSSION
0
null
null
19,273,628
null
This study revealed an important role of CX3CR1 in the recruitment of CD115+
null
76
39,486
0
false
null
null
This study revealed an important role of CX3CR1 in the recruitment of CD115+
true
true
false
true
false
6,814
1
DISCUSSION
0
null
null
19,273,628
null
+ inflammatory monocytes, which are immediate precursors to TipDCs, to the spleen during infection and for the control of bacterial growth during primary infection in two different strains of mice (C57BL/6 and BALB/c).
null
218
39,487
0
false
null
null
+ inflammatory monocytes, which are immediate precursors to TipDCs, to the spleen during infection and for the control of bacterial growth during primary infection in two different strains of mice (C57BL/6 and BALB/c).
false
false
true
true
false
6,814
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
Impaired recruitment of CX3CR1-deficient Gr1+ monocytes/
[ "44" ]
56
39,488
0
false
Impaired recruitment of CX3CR1-deficient Gr1+ monocytes/
[]
Impaired recruitment of CX3CR1-deficient Gr1+ monocytes/
true
true
false
true
false
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
TipDCs is the most likely mechanism underlying our observations for the following reasons: in situ hybridization experiments (Fig.
[ "44" ]
130
39,489
0
false
TipDCs is the most likely mechanism underlying our observations for the following reasons: in situ hybridization experiments (Fig.
[]
TipDCs is the most likely mechanism underlying our observations for the following reasons: in situ hybridization experiments (Fig.
true
true
true
true
true
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
S4) indicated that fractalkine is expressed in the marginal zone/T cell areas of the spleen, where TipDC accumulate during infection (Fig.
[ "44" ]
138
39,490
0
false
S4) indicated that fractalkine is expressed in the marginal zone/T cell areas of the spleen, where TipDC accumulate during infection (Fig.
[]
S4) indicated that fractalkine is expressed in the marginal zone/T cell areas of the spleen, where TipDC accumulate during infection (Fig.
true
true
true
true
true
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
5) (44); short-term adoptive transfer of BM monocytes into irradiated hosts decreased the accumulation of CX3CR1-deficient monocytes in the spleen by a factor of ten (see Fig.
[ "44" ]
175
39,491
1
false
5) ; short-term adoptive transfer of BM monocytes into irradiated hosts decreased the accumulation of CX3CR1-deficient monocytes in the spleen by a factor of ten (see Fig.
[ "44" ]
5) ; short-term adoptive transfer of BM monocytes into irradiated hosts decreased the accumulation of CX3CR1-deficient monocytes in the spleen by a factor of ten (see Fig.
false
false
true
true
false
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
4); during acute Lm infection, the number of monocytes was higher in the blood of infected CX3CR1-deficient mice but decreased in the spleen (Fig.
[ "44" ]
146
39,492
0
false
4); during acute Lm infection, the number of monocytes was higher in the blood of infected CX3CR1-deficient mice but decreased in the spleen (Fig.
[]
4); during acute Lm infection, the number of monocytes was higher in the blood of infected CX3CR1-deficient mice but decreased in the spleen (Fig.
false
false
true
true
false
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
4), and the frequency of annexin-Vhigh monocytes was not increased in spleen from infected CX3CR1-deficient mice (Fig.
[ "44" ]
118
39,493
0
false
4), and the frequency of annexin-Vhigh monocytes was not increased in spleen from infected CX3CR1-deficient mice (Fig.
[]
4), and the frequency of annexin-Vhigh monocytes was not increased in spleen from infected CX3CR1-deficient mice (Fig.
false
false
true
true
false
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
S6); CX3CR1 deficiency does not appear to influence the survival of CD115+ Gr1+ monocytes in the periphery (Fig.
[ "44" ]
112
39,494
0
false
S6); CX3CR1 deficiency does not appear to influence the survival of CD115+ Gr1+ monocytes in the periphery (Fig.
[]
S6); CX3CR1 deficiency does not appear to influence the survival of CD115+ Gr1+ monocytes in the periphery (Fig.
true
true
true
true
true
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
S9); and finally, we have found that CX3CR1 was redundant for MDP development, survival, homing to the spleen, and differentiation in vivo and in vitro (Fig.
[ "44" ]
157
39,495
0
false
S9); and finally, we have found that CX3CR1 was redundant for MDP development, survival, homing to the spleen, and differentiation in vivo and in vitro (Fig.
[]
S9); and finally, we have found that CX3CR1 was redundant for MDP development, survival, homing to the spleen, and differentiation in vivo and in vitro (Fig.
true
true
true
true
true
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
S10) and MDP-derived spleen
[ "44" ]
27
39,496
0
false
S10) and MDP-derived spleen
[]
S10) and MDP-derived spleen
true
true
false
true
false
6,815
2
DISCUSSION
1
44
[ "bib44" ]
19,273,628
NA
PDCs appear to develop normally.
[ "44" ]
32
39,497
0
false
PDCs appear to develop normally.
[]
PDCs appear to develop normally.
true
true
true
true
true
6,815
3
DISCUSSION
1
29
[ "bib29", "bib47", "bib38", "bib42", "bib42", "bib38", "bib48", "bib49" ]
19,273,628
NA|NA|NA|NA|NA|NA|NA|NA
It is of note that although CD115+ Gr1+ (CX3CR1low) inflammatory monocytes were present in normal numbers in both CX3CR1- and CX3CL1-deficient mice, the present data confirm that CX3CR1 deficiency also slightly decreases the survival of the CD115+ Gr1− monocytes (Fig.
[ "29", "47", "38", "42", "42", "38", "48", "49" ]
268
39,498
0
false
It is of note that although CD115+ Gr1+ (CX3CR1low) inflammatory monocytes were present in normal numbers in both CX3CR1- and CX3CL1-deficient mice, the present data confirm that CX3CR1 deficiency also slightly decreases the survival of the CD115+ Gr1− monocytes (Fig.
[]
It is of note that although CD115+ Gr1+ (CX3CR1low) inflammatory monocytes were present in normal numbers in both CX3CR1- and CX3CL1-deficient mice, the present data confirm that CX3CR1 deficiency also slightly decreases the survival of the CD115+ Gr1− monocytes (Fig.
true
true
true
true
true
6,816
3
DISCUSSION
1
29
[ "bib29", "bib47", "bib38", "bib42", "bib42", "bib38", "bib48", "bib49" ]
19,273,628
NA|NA|NA|NA|NA|NA|NA|NA
This result was expected and consistent with the conclusions that we made from our earlier adoptive transfer experiments (29) and with a more recent study (47).
[ "29", "47", "38", "42", "42", "38", "48", "49" ]
160
39,499
1
false
This result was expected and consistent with the conclusions that we made from our earlier adoptive transfer experiments and with a more recent study.
[ "29", "47" ]
This result was expected and consistent with the conclusions that we made from our earlier adoptive transfer experiments and with a more recent study.
true
true
true
true
true
6,816
3
DISCUSSION
1
29
[ "bib29", "bib47", "bib38", "bib42", "bib42", "bib38", "bib48", "bib49" ]
19,273,628
NA|NA|NA|NA|NA|NA|NA|NA
CX3CR1 has been previously shown to be important for the adhesion of CD115+ Gr1− (CX3CR1high) monocytes to the endothelium of blood vessels (38, 42).
[ "29", "47", "38", "42", "42", "38", "48", "49" ]
149
39,500
0
false
CX3CR1 has been previously shown to be important for the adhesion of CD115+ Gr1− (CX3CR1high) monocytes to the endothelium of blood vessels.
[ "38, 42" ]
CX3CR1 has been previously shown to be important for the adhesion of CD115+ Gr1− (CX3CR1high) monocytes to the endothelium of blood vessels.
true
true
true
true
true
6,816
3
DISCUSSION
1
42
[ "bib29", "bib47", "bib38", "bib42", "bib42", "bib38", "bib48", "bib49" ]
19,273,628
NA|NA|NA|NA|NA|NA|NA|NA
The mechanism underlying the selective survival defect of CD115+ Gr1− CX3CR1high monocytes may thus be related to the unique patrolling behavior of these cells, which attach themselves to the luminal side of the endothelium via a CX3CR1- and LFA1-dependent mechanism, crawling onto the endothelium for considerable perio...
[ "29", "47", "38", "42", "42", "38", "48", "49" ]
358
39,501
1
false
The mechanism underlying the selective survival defect of CD115+ Gr1− CX3CR1high monocytes may thus be related to the unique patrolling behavior of these cells, which attach themselves to the luminal side of the endothelium via a CX3CR1- and LFA1-dependent mechanism, crawling onto the endothelium for considerable perio...
[ "42" ]
The mechanism underlying the selective survival defect of CD115+ Gr1− CX3CR1high monocytes may thus be related to the unique patrolling behavior of these cells, which attach themselves to the luminal side of the endothelium via a CX3CR1- and LFA1-dependent mechanism, crawling onto the endothelium for considerable perio...
true
true
true
true
true
6,816
3
DISCUSSION
1
38
[ "bib29", "bib47", "bib38", "bib42", "bib42", "bib38", "bib48", "bib49" ]
19,273,628
NA|NA|NA|NA|NA|NA|NA|NA
Human CX3CR1high cells also adhere to the endothelium via a CX3CR1-dependent mechanism (38), and adhesion is known to increase survival as has been shown for CX3CR1-expressing cells binding to CX3CL1 via a mechanism involving an Akt/GSK-3β–mediated antiapoptotic signaling pathway (48, 49).
[ "29", "47", "38", "42", "42", "38", "48", "49" ]
290
39,502
1
false
Human CX3CR1high cells also adhere to the endothelium via a CX3CR1-dependent mechanism, and adhesion is known to increase survival as has been shown for CX3CR1-expressing cells binding to CX3CL1 via a mechanism involving an Akt/GSK-3β–mediated antiapoptotic signaling pathway.
[ "38", "48, 49" ]
Human CX3CR1high cells also adhere to the endothelium via a CX3CR1-dependent mechanism, and adhesion is known to increase survival as has been shown for CX3CR1-expressing cells binding to CX3CL1 via a mechanism involving an Akt/GSK-3β–mediated antiapoptotic signaling pathway.
true
true
true
true
true
6,816
4
DISCUSSION
1
45
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
The role of CX3CR1 for the recruitment of CD115+ Gr1+ monocytes/TipDC precursors is reminiscent of the phenotype of CCR2-, MCP1-, and MCP3- deficient mice (45, 50).
[ "45", "50", "45", "46", "50", "46" ]
164
39,503
0
false
The role of CX3CR1 for the recruitment of CD115+ Gr1+ monocytes/TipDC precursors is reminiscent of the phenotype of CCR2-, MCP1-, and MCP3- deficient mice.
[ "45, 50" ]
The role of CX3CR1 for the recruitment of CD115+ Gr1+ monocytes/TipDC precursors is reminiscent of the phenotype of CCR2-, MCP1-, and MCP3- deficient mice.
true
true
true
true
true
6,817
4
DISCUSSION
1
45
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
However, the disruption of the CCR2 axis results in a much more dramatic phenotype because both Gr1+ monocytes exit from the BM into the bloodstream, and the recruitment into tissues of the few monocytes that exit the BM is impaired in these mice (45, 46, 50).
[ "45", "50", "45", "46", "50", "46" ]
260
39,504
0
false
However, the disruption of the CCR2 axis results in a much more dramatic phenotype because both Gr1+ monocytes exit from the BM into the bloodstream, and the recruitment into tissues of the few monocytes that exit the BM is impaired in these mice.
[ "45, 46, 50" ]
However, the disruption of the CCR2 axis results in a much more dramatic phenotype because both Gr1+ monocytes exit from the BM into the bloodstream, and the recruitment into tissues of the few monocytes that exit the BM is impaired in these mice.
true
true
true
true
true
6,817
4
DISCUSSION
1
45
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
Thus CCR2-deficient mice have reduced numbers of TipDCs.
[ "45", "50", "45", "46", "50", "46" ]
56
39,505
0
false
Thus CCR2-deficient mice have reduced numbers of TipDCs.
[]
Thus CCR2-deficient mice have reduced numbers of TipDCs.
true
true
true
true
true
6,817
4
DISCUSSION
1
45
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
In contrast, BM output is intact in CX3CR1-deficient mice, the number of blood Gr1+ monocytes are normal, and only their recruitment is impaired.
[ "45", "50", "45", "46", "50", "46" ]
145
39,506
0
false
In contrast, BM output is intact in CX3CR1-deficient mice, the number of blood Gr1+ monocytes are normal, and only their recruitment is impaired.
[]
In contrast, BM output is intact in CX3CR1-deficient mice, the number of blood Gr1+ monocytes are normal, and only their recruitment is impaired.
true
true
true
true
true
6,817
4
DISCUSSION
1
46
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
Similarly, CCR2-deficient mice have a dramatically impaired innate response to Lm infection and die of infection within a few days (46), whereas CX3CR1-deficient hosts exhibit a reduced clearance of Lm at 24 h after infections (Fig.
[ "45", "50", "45", "46", "50", "46" ]
232
39,507
1
false
Similarly, CCR2-deficient mice have a dramatically impaired innate response to Lm infection and die of infection within a few days, whereas CX3CR1-deficient hosts exhibit a reduced clearance of Lm at 24 h after infections (Fig.
[ "46" ]
Similarly, CCR2-deficient mice have a dramatically impaired innate response to Lm infection and die of infection within a few days, whereas CX3CR1-deficient hosts exhibit a reduced clearance of Lm at 24 h after infections (Fig.
true
true
true
true
true
6,817
4
DISCUSSION
1
45
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
3), but at later time points we did not observe significant differences in the survival of CX3CR1-deficient and control mice (not depicted).
[ "45", "50", "45", "46", "50", "46" ]
140
39,508
0
false
3), but at later time points we did not observe significant differences in the survival of CX3CR1-deficient and control mice (not depicted).
[]
3), but at later time points we did not observe significant differences in the survival of CX3CR1-deficient and control mice (not depicted).
false
false
true
true
false
6,817
4
DISCUSSION
1
45
[ "bib45", "bib50", "bib45", "bib46", "bib50", "bib46" ]
19,273,628
NA|NA|NA|NA|NA|NA
We therefore propose that CX3CR1 may play an important role in mediating the recruitment of CD115+ Gr1+ inflammatory monocytes in the white pulp of the spleen during acute inflammation, possibly through adhesion to the capillary endothelial cells of the marginal zone of the spleen.
[ "45", "50", "45", "46", "50", "46" ]
282
39,509
0
false
We therefore propose that CX3CR1 may play an important role in mediating the recruitment of CD115+ Gr1+ inflammatory monocytes in the white pulp of the spleen during acute inflammation, possibly through adhesion to the capillary endothelial cells of the marginal zone of the spleen.
[]
We therefore propose that CX3CR1 may play an important role in mediating the recruitment of CD115+ Gr1+ inflammatory monocytes in the white pulp of the spleen during acute inflammation, possibly through adhesion to the capillary endothelial cells of the marginal zone of the spleen.
true
true
true
true
true
6,817
0
INTRODUCTION
1
1
[ "B1", "B2", "B3", "B4", "B5", "B6" ]
18,162,708
pmid-3056758|pmid-9279450|pmid-8971083|pmid-9686693|pmid-11368702|NA|pmid-9603539|pmid-3056758|pmid-9279450|NA
It has long been recognized that insulin resistance syndrome (IRS) encompasses insulin resistance, hyperinsulinemia, hypertension, dyslipidemia, diabetes, impaired glucose intolerance, and obesity.
[ "1", "2", "3", "4", "5", "6" ]
197
39,510
0
false
It has long been recognized that insulin resistance syndrome (IRS) encompasses insulin resistance, hyperinsulinemia, hypertension, dyslipidemia, diabetes, impaired glucose intolerance, and obesity.
[]
It has long been recognized that insulin resistance syndrome (IRS) encompasses insulin resistance, hyperinsulinemia, hypertension, dyslipidemia, diabetes, impaired glucose intolerance, and obesity.
true
true
true
true
true
6,818
0
INTRODUCTION
1
1
[ "B1", "B2", "B3", "B4", "B5", "B6" ]
18,162,708
pmid-3056758|pmid-9279450|pmid-8971083|pmid-9686693|pmid-11368702|NA|pmid-9603539|pmid-3056758|pmid-9279450|NA
Reaven (1) designated this clinical syndrome as "Syndrome X" in 1988.
[ "1", "2", "3", "4", "5", "6" ]
69
39,511
1
false
Reaven designated this clinical syndrome as "Syndrome X" in 1988.
[ "1" ]
Reaven designated this clinical syndrome as "Syndrome X" in 1988.
true
true
true
true
true
6,818
0
INTRODUCTION
1
2
[ "B1", "B2", "B3", "B4", "B5", "B6" ]
18,162,708
pmid-3056758|pmid-9279450|pmid-8971083|pmid-9686693|pmid-11368702|NA|pmid-9603539|pmid-3056758|pmid-9279450|NA
More recently, it has been called "metabolic syndrome", "plurimetabolic syndrome", "dysmetabolic syndrome", "deadly quartet", or "major cardiovascular risk factor syndrome" (2), with concomitant difficulties for standardized studies because of unclear diagnostic criteria (3).
[ "1", "2", "3", "4", "5", "6" ]
276
39,512
1
false
More recently, it has been called "metabolic syndrome", "plurimetabolic syndrome", "dysmetabolic syndrome", "deadly quartet", or "major cardiovascular risk factor syndrome", with concomitant difficulties for standardized studies because of unclear diagnostic criteria.
[ "2", "3" ]
More recently, it has been called "metabolic syndrome", "plurimetabolic syndrome", "dysmetabolic syndrome", "deadly quartet", or "major cardiovascular risk factor syndrome", with concomitant difficulties for standardized studies because of unclear diagnostic criteria.
true
true
true
true
true
6,818
0
INTRODUCTION
1
4
[ "B1", "B2", "B3", "B4", "B5", "B6" ]
18,162,708
pmid-3056758|pmid-9279450|pmid-8971083|pmid-9686693|pmid-11368702|NA|pmid-9603539|pmid-3056758|pmid-9279450|NA
Since the causes of insulin resistance had not yet been identified, in 1998, the WHO named this disease entity "metabolic syndrome" rather than "insulin resistance syndrome" and suggested diagnostic criteria including hypertension, dyslipidemia, obesity, microproteinuria, diabetes, or impaired glucose intolerance as co...
[ "1", "2", "3", "4", "5", "6" ]
333
39,513
1
false
Since the causes of insulin resistance had not yet been identified, in 1998, the WHO named this disease entity "metabolic syndrome" rather than "insulin resistance syndrome" and suggested diagnostic criteria including hypertension, dyslipidemia, obesity, microproteinuria, diabetes, or impaired glucose intolerance as co...
[ "4" ]
Since the causes of insulin resistance had not yet been identified, in 1998, the WHO named this disease entity "metabolic syndrome" rather than "insulin resistance syndrome" and suggested diagnostic criteria including hypertension, dyslipidemia, obesity, microproteinuria, diabetes, or impaired glucose intolerance as co...
true
true
true
true
true
6,818
0
INTRODUCTION
1
1
[ "B1", "B2", "B3", "B4", "B5", "B6" ]
18,162,708
pmid-3056758|pmid-9279450|pmid-8971083|pmid-9686693|pmid-11368702|NA|pmid-9603539|pmid-3056758|pmid-9279450|NA
Actually, these diagnostic criteria generally were not available due to the limitations of diagnostic procedures such as the measurement of microproteinuria, which required a 24 hr time period to obtain results.
[ "1", "2", "3", "4", "5", "6" ]
211
39,514
0
false
Actually, these diagnostic criteria generally were not available due to the limitations of diagnostic procedures such as the measurement of microproteinuria, which required a 24 hr time period to obtain results.
[]
Actually, these diagnostic criteria generally were not available due to the limitations of diagnostic procedures such as the measurement of microproteinuria, which required a 24 hr time period to obtain results.
true
true
true
true
true
6,818
0
INTRODUCTION
1
5
[ "B1", "B2", "B3", "B4", "B5", "B6" ]
18,162,708
pmid-3056758|pmid-9279450|pmid-8971083|pmid-9686693|pmid-11368702|NA|pmid-9603539|pmid-3056758|pmid-9279450|NA
The Adult Treatment Panel (ATP) report of the National Cholesterol Education Program (NCEP) suggested new diagnostic criteria in 2001 (5).
[ "1", "2", "3", "4", "5", "6" ]
138
39,515
1
false
The Adult Treatment Panel (ATP) report of the National Cholesterol Education Program (NCEP) suggested new diagnostic criteria in 2001.
[ "5" ]
The Adult Treatment Panel (ATP) report of the National Cholesterol Education Program (NCEP) suggested new diagnostic criteria in 2001.
true
true
true
true
true
6,818